Inactivation of SARS-CoV-2 infectivity in platelet concentrates or plasma following treatment with ultraviolet C light or with methylene blue combined with visible light

Jody Hobson-Peters; Alberto A Amarilla; Lina Rustanti; Denese C Marks; Eileen Roulis; Alexander A Khromykh; Naphak Modhiran; Daniel Watterson; Stefan Reichenberg; Frank Tolksdorf; Chryslain Sumian; Axel Seltsam; Ute Gravemann; Helen M Faddy

doi:10.1111/trf.17238

Back

Inactivation of SARS-CoV-2 infectivity in platelet concentrates or plasma following treatment with ultraviolet C light or with methylene blue combined with visible light

Journal article

Open access

Peer reviewed

Inactivation of SARS-CoV-2 infectivity in platelet concentrates or plasma following treatment with ultraviolet C light or with methylene blue combined with visible light

Jody Hobson-Peters, Alberto A Amarilla, Lina Rustanti, Denese C Marks, Eileen Roulis, Alexander A Khromykh, Naphak Modhiran, Daniel Watterson, Stefan Reichenberg, Frank Tolksdorf, …

Transfusion, Vol.63(2), pp.288-293

2023

DOI: https://doi.org/10.1111/trf.17238

PMID: 36573801

Files and links (2)

pdf

Transfusion - 2022 - Hobson‐Peters - Inactivation of SARS‐CoV‐2 infectivity in platelet concentrates or plasma following-VoR1.11 MBDownload View

Published VersionCC BY-NC-ND V4.0, Open Access

url

https://doi.org/10.1111/trf.17238View

Published Version

Abstract

emerging infectious disease

transfusion-transmission

SARS-CoV-2

pathogen inactivation

safety

plasma

platelets

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unlikely to be a major transfusion-transmitted pathogen; however, convalescent plasma is a treatment option used in some regions. The risk of transfusion-transmitted infections can be minimized by implementing Pathogen Inactivation (PI), such as THERAFLEX MB-plasma and THERAFLEX UV-Platelets systems. Here we examined the capability of these PI systems to inactivate SARS-CoV-2. Study Design and Methods: SARS-CoV-2 spiked plasma units were treated using the THERAFLEX MB-Plasma system in the presence of methylene blue (~0.8 μmol/L; visible light doses: 20, 40, 60, and 120 [standard] J/cm2). SARS-CoV-2 spiked platelet concentrates (PCs) were treated using the THERAFLEX UV-platelets system (UVC doses: 0.05, 0.10, 0.15, and 0.20 [standard] J/cm2). Samples were taken prior to the first and after each illumination dose, and viral infectivity was assessed using an immunoplaque assay. Results: Treatment of spiked plasma with the THERAFLEX MB-Plasma system resulted in an average ≥5.03 log10 reduction in SARS-CoV-2 infectivity at one third (40 J/cm2) of the standard visible light dose. For the platelet concentrates (PCs), treatment with the THERAFLEX UV-Platelets system resulted in an average ≥5.18 log10 reduction in SARS-CoV-2 infectivity at the standard UVC dose (0.2 J/cm2). Conclusions: SARS-CoV-2 infectivity was reduced in plasma and platelets following treatment with the THERAFLEX MB-Plasma and THERAFLEX UV-Platelets systems, to the limit of detection, respectively. These PI technologies could therefore be an effective option to reduce the risk of transfusion-transmitted emerging pathogens.

Details

Title: Inactivation of SARS-CoV-2 infectivity in platelet concentrates or plasma following treatment with ultraviolet C light or with methylene blue combined with visible light
Authors: Jody Hobson-Peters (Corresponding Author) - The University of Queensland
Alberto A Amarilla (Author) - The University of Queensland
Lina Rustanti (Author) - Australian Red Cross Lifeblood
Denese C Marks (Author) - Australian Red Cross Lifeblood
Eileen Roulis (Author) - Australian Red Cross Lifeblood
Alexander A Khromykh (Author) - The University of Queensland
Naphak Modhiran (Author) - School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia
Daniel Watterson (Author) - Australian Infectious Diseases Research Centre, Global Virus Network Centre of Excellence, Brisbane, QLD, Australia
Stefan Reichenberg (Author) - Macopharma International GmbH, Langen, Germany
Frank Tolksdorf (Author) - Macopharma International GmbH, Langen, Germany
Chryslain Sumian (Author) - Macopharma
Axel Seltsam (Author) - Bavarian Red Cross Blood Service, Nuremberg, Germany
Ute Gravemann (Author) - German Red Cross Blood Service NSTOB, Springe, Germany
Helen M Faddy (Author) - University of the Sunshine Coast, Queensland, School of Health - Biomedicine
Publication details: Transfusion, Vol.63(2), pp.288-293
Publisher: Wiley-Blackwell Publishing, Inc.
Date published: 2023
DOI: 10.1111/trf.17238
ISSN: 1537-2995; 0041-1132
PMID: 36573801
Copyright note: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2023 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.
Organisation Unit: School of Health - Biomedicine; School of Health and Behavioural Sciences - Legacy
Language: English
Record Identifier: 99698697802621
Output Type: Journal article

Metrics

2 File views/ downloads

34 Record Views

2 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Web Of Science research areas: Hematology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites